Concepedia

Publication | Open Access

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

DOIFull Paper Access

74

Citations

21

References

2023

Year

Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu,
The Lancet Diabetes & Endocrinology

Abstract

Boehringer Ingelheim and Eli Lilly.

References

YearCitations

Page 1